FIELD: medicine; ophthalmology.
SUBSTANCE: group of inventions is intended for the treatment of allergies. The ophthalmic composition for the treatment of allergies contains brimonidine and ketotifen. Also, the composition may contain polysorbate, hydroxypropyl methylcellulose and citrate buffer, while pH of the specified composition is about 6.5. The components of the composition are used in the claimed amounts. In other embodiments, methods of treating or preventing an allergic response are provided.
EFFECT: effective treatment or prevention of allergies, including reduction of redness of the eyes.
14 cl, 1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR INTEGRATED TREATMENT OF PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA AND OCULAR SURFACE DISEASES | 2013 |
|
RU2517033C1 |
| COMPOSITION FOR INTEGRATED TREATMENT OF PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA AND OCULAR SURFACE DISEASES | 2011 |
|
RU2464985C1 |
| METHODS AND COMPOSITIONS FOR TREATING PRESBYOPIA, MYDRIASIS AND OTHER OCULAR DISORDERS | 2019 |
|
RU2824137C2 |
| OPHTHALMIC DROPS FOR TREATING ALLERGIC CONJUNCTIVITIS AND KERATOCONJUNCTIVITIS | 2001 |
|
RU2193403C1 |
| INTRAOCULAR DRUG DELIVERY SYSTEMS | 2007 |
|
RU2440102C2 |
| OPHTHALMIC PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2734344C2 |
| STABILIZED AND CONSERVED EYE COMPOSITIONS CONTAINING KETOTIFEN | 2006 |
|
RU2442583C2 |
| INTRAOCULAR SYSTEMS OF SUSTAINED-RELEASE DRUG DELIVERY AND METHOD OF TREATING OPHTHALMIC DISEASES | 2010 |
|
RU2532333C2 |
| IMPROVED METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF TELANGIECTASIA | 2011 |
|
RU2535008C2 |
| COMPOSITION IN THE FORM OF EYE DROPS TO DECREASE INTRAOCULAR PRESSURE | 2017 |
|
RU2772230C2 |
